An overview of the Phase 1 Trial of TPI-287/Temezolomide in Neuroblastoma and Medulloblastoma

This webinar was recorded on August 26, 2009

An overview of TPI 287/Temezolomide in Neuroblastoma from Neuroblastoma Foundation on Vimeo.

Dr. Giselle Sholler, principal investigator and pediatric oncologist from Vermont Cancer Center, will be presenting important information regarding the newly opened "Phase 1 Trial of TPI 287 as a Single Agent and in Combination with Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma."  This presentation is intended for parents and caregivers of children with refractory or recurrent neuroblastoma and medulloblastoma.  Dr. Sholler will provide an overview of the preclinical research leading up to the trial.  She will also be discussing the rationale behind the trial, the purpose of the study, and the eligibility requirements.  Dr. Sholler will share a summary of the treatment plan and delve into some of the patient experiences that have been seen previously.  Parents of children that have participated in this trial will also be available to share their experiences.  The presentation will be followed with a question and answer session.

Participation in this online seminar will provide you with the information necessary to aid your and your child’s oncologist in deciding whether this trial may or may not be appropriate for your child.  Please join us for the hour long presentation and question and answer session on Wednesday, August 26, 2009 at 12:00PM CST.

Title:   An overview of the Phase 1 Trial of TPI 287/Temezolomide in Neuroblastoma and Medulloblastoma
Date: Wednesday, August 26, 2009
Time: 12:00 PM - 1:00 PM CDT

After registering you will receive a confirmation email containing information about joining the Webinar.

System Requirements
PC-based attendees
Required: Windows® 2000, XP Home, XP Pro, 2003 Server, Vista
Macintosh®-based attendees
Required: Mac OS® X 10.4 (Tiger®) or newer

Space is limited.
Reserve your Webinar seat now at:
https://www2.gotomeeting.com/register/601120458

Posted 19 Aug 2009 10:36 AM by Mark Dungan
Filed under: , , ,

Comments

http://dxczigpoaawk.com/ wrote re: An overview of the Phase 1 Trial of TPI-287/Temezolomide in Neuroblastoma and Medulloblastoma
on 14 Jun 2010 12:00 AM

yXJxHt  <a href="ubooboodffjg.com/.../a>, [url=http://ietypoqhsrul.com/]ietypoqhsrul[/url], [link=http://jfpvfshqxpzv.com/]jfpvfshqxpzv[/link], http://vzjikjloicpa.com/

http://eodbansxwpwr.com/ wrote re: An overview of the Phase 1 Trial of TPI-287/Temezolomide in Neuroblastoma and Medulloblastoma
on 17 Jun 2010 8:45 AM

YFuQi7  <a href="mxcngulwdthl.com/.../a>, [url=http://ztnuwasjnfrt.com/]ztnuwasjnfrt[/url], [link=http://tqecikijwodh.com/]tqecikijwodh[/link], http://ezfnqvrybiaf.com/

Add a Comment

(required)
(optional)
(required)  
Remember Me?
Seten amet diorl oprta ahsellu miokiste porta.

Bean nonumy hendrit mauris phelus porta. Fusce suscipit varius ui. Fusce feugiat malesada odio. Morbi nunc odio, gravida sit cursusnec, luctus aorem. auris phelus porta ae. Fusce suscipit varius ui. Fusce feug.

Read More

There is nothing quite as devastating as hearing that word - neuroblastoma. In seconds your world is turned upside down and your normal life is but a distant memory. You are thrust into a confusing world full of fear. Your child has cancer.

We know. We have been there. The Neuroblastoma Foundation is here for you.

Welcome to our website. It is a place for you to find answers and ask questions. One of the primary goals of the Neuroblastoma Foundation is to ensure that parents, patients and health care professionals find the information they need to make the best treatment decisions possible for children and adults affected by neuroblastoma. There is a vast amount of information throughout the internet, much of which is encapsulated in medical jargon that is so complex that even many medical professionals have difficulty in interpreting its meaning. We are here to help to decipher this information and to make sure you (and your oncologist) understand exactly what it means to you. From treatment decisions to side effects we have parents and experts that have experienced it all and are willing to distill it for you.